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γ-Hydroxybutyric acid (GHB) reduces (a) alcohol intake and alcohol motivational properties
in alcohol-preferring rats and (b) alcohol drinking and craving for alcohol in human alco-
holics. The present study was designed to extend to relapse-like drinking the capacity of
GHB to suppress different alcohol-related behaviors in alcohol-preferring rats. The “alco-
hol deprivation effect,” defined as the temporary increase in alcohol intake occurring in
laboratory animals after a period of alcohol deprivation, was used as model of alcohol
relapse. Acute administration of non-sedative doses of GHB (0, 100, 200, and 300 mg/kg,
i.p.) resulted in the complete suppression of the extra-amount of alcohol consumed by
Sardinian alcohol-preferring rats during the first hour of re-access to alcohol after a 14-day
period of deprivation. These data demonstrate that GHB suppressed relapse-like drinking
in a rat model of excessive alcohol consumption.
Keywords: γ-hydroxybutyric acid, alcohol deprivation effect, relapse-like drinking, GABAB receptor, Sardinian
alcohol-preferring rats
INTRODUCTION
The short-chain fatty acid,γ-hydroxybutyric acid (GHB; see Snead
and Gibson, 2005; Agabio et al., 2010), has been used for years – in
some European Countries – in the treatment of alcohol depen-
dence. Several open and double-blind clinical surveys indicate
indeed that GHB administration reduced alcohol craving and con-
sumption, promoted abstinence, and ameliorated alcohol with-
drawal syndrome in alcoholics. Specifically, a small double-blind
study (Gallimberti et al., 1992) and some subsequent open studies
(Addolorato et al., 1996, 1998; Moncini et al., 2000; Maremmani
et al., 2001; Caputo et al., 2003, 2007, 2011) indicated that treat-
ment with GHB was effective in reducing alcohol drinking, pro-
moting abstinence, and controlling craving for alcohol (for review,
see Agabio and Gessa, 2002; Addolorato et al., 2009). Further, three
double-blind studies (Gallimberti et al., 1989; Addolorato et al.,
1999a; Nimmerrichter et al., 2002) and some additional open stud-
ies (Nava et al., 2007; Elsing et al., 2009) reported that treatment
with GHB was also effective in suppressing the symptomatology of
alcohol withdrawal syndrome (for review, see Agabio and Gessa,
2002; Addolorato et al., 2009). In terms of mechanism of action,
the similarity of the pharmacological profile of GHB and alco-
hol has led to hypothesize that the suppressing effects exerted by
GHB on alcohol withdrawal syndrome, alcohol consumption, and
craving for alcohol may be due to the “substitution” of alcohol
actions, similar to methadone in heroin addiction (see Agabio and
Gessa, 2002; Addolorato et al., 2009). As predictable on the basis of
a number of clinical and preclinical observations (see Nicholson
and Balster, 2001; Drasbek et al., 2006), the major limitation of the
therapeutic use of GHB appears to be its abuse potential: a por-
tion of patients undergoing GHB treatment voluntarily increased
their daily GHB dosage (although some of these self-administered
increases were made in an attempt to achieve more effective ther-
apeutic doses) (Addolorato et al., 1996; Gallimberti et al., 2000;
Glisson and Norton, 2002; Caputo et al., 2011) and some patients
even developed dependence on GHB (Addolorato et al., 1999b; see
also Caputo et al., 2009).
Treatment with GHB reduced several alcohol-related behav-
iors also in laboratory rodents. Specifically, administration of
non-sedative doses of GHB markedly reduced voluntary alco-
hol intake in selectively bred, Indiana alcohol-preferring (June
et al., 1995) and Sardinian alcohol-preferring (sP) (Agabio et al.,
1998) rats exposed to the standard, homecage two-bottle “alco-
hol vs. water” choice regimen. Additionally, administration of
non-sedative doses of GHB reduced the motivational properties
of alcohol (the animal correlate of human craving for alcohol),
measured in sP rats exposed to sessions of operant, oral alcohol
self-administration under the progressive ratio schedule of rein-
forcement (Maccioni et al., 2008). Treatment with non-sedative
doses of GHB also reduced alcohol-seeking behavior, measured
in sP rats initially trained to lever-respond for alcohol under
a standard procedure of oral alcohol self-administration and
then exposed, in the test session, to extinction responding (non-
reinforced lever-responding was used as index of alcohol-seeking
behavior) (Maccioni et al., 2008). Finally, administration of GHB
resulted in the complete suppression of the severity of alcohol
withdrawal signs in rats made physically dependent on alcohol
by the repeated, forced administration of intoxicating doses of
alcohol (Fadda et al., 1989).
The present study was designed to extend to alcohol relapse-like
drinking the investigation on the capacity of GHB to suppress dif-
ferent alcohol-related behaviors in rats. To this end, sP rats were
exposed to the “alcohol deprivation effect” (ADE) paradigm, a
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validated animal model of relapse episodes occurring in human
alcoholics. Relapse to heavy alcohol drinking, together with loss of
control over alcohol, represent the core features of alcohol addic-
tion in humans (see Morse and Flavin, 1992; Kleber et al., 2007).
ADE is defined as the temporary increase in alcohol drinking
occurring after a period of alcohol abstinence (see Spanagel, 2005;
Martin-Fardon and Weiss, 2013). Rats of the sP line constitute a
good experimental model for investigations on ADE. Indeed, sP
rats display robust, although transient, increases in alcohol intake
after a period of alcohol deprivation of at least 1 week: over the
first hour of re-access to alcohol, alcohol intake in sP rats is usu-
ally double than that recorded in control, alcohol-non-deprived
rats (e.g., Agabio et al., 2000; Serra et al., 2003).
MATERIALS AND METHODS
All experimental procedures employed in the present study were
in accordance with the Italian Law on the “Protection of animals
used for experimental and other scientific reasons.”
ANIMALS
Male sP rats (see Colombo et al., 2006a; Bell et al., 2012), from the
71st generation and 75-days-old at the start of the study, were used.
Rats were individually housed in standard plastic cages with wood
chip bedding. The animal facility was under an inverted 12:12 h
light-dark cycle (lights on at 23:00), at a constant temperature of
22± 2˚C, and relative humidity of approximately 60%. Rats were
extensively habituated to handling and intraperitoneal injections.
Standard rat chow (Mucedola, Settimo Milanese, Italy) was always
available.
EXPERIMENTAL PROCEDURE
Rats (n= 64) were continuously offered alcohol (10% v/v, in
water) and water under the standard, homecage two-bottle choice
regimen, with unlimited access for 24 h/day and for four con-
secutive weeks. Alcohol, water, and food intake was monitored
once a day by weighing the bottles and food pellets (0.1-g accu-
racy) immediately before the onset of the dark phase. Bottles were
refilled every day with fresh solution and their left-right positions
interchanged daily.
At the end of the 4-week period of access to alcohol and water,
during which rats consumed daily an average of approximately
6 g/kg alcohol, rats were divided into two groups (n= 32) matched
for body weight as well as alcohol and water intake over the last
7 days. One rat group was deprived of alcohol for 14 consecutive
days, during which water was the sole fluid available (alcohol-
deprived rats). The second rat group continued to have unlimited
access to alcohol and water (alcohol-non-deprived rats), with the
exception of the last 6 h before GHB injection, when the alcohol
bottle was removed to ensure that blood alcohol levels were equal
to zero at the time of the test.
At the end of the 14th day of the deprivation phase, rats of
both groups were divided into four subgroups (n= 8), matched
for body weight, and injected acutely and intraperitoneally with
0, 100, 200, and 300 mg/kg GHB. GHB (sodium salt; Laboratorio
Farmaceutico CT, Sanremo, Italy) was dissolved in distilled water
[3.4% w/v; this concentration (kept fixed in the three doses of
GHB) was chosen to minimize tissue irritation at the injection site
(e.g., Maccioni et al., 2008)] and administered 10–15 min before
lights off. Control rats (0 mg/kg GHB) were treated with an equal
volume of saline. Alcohol was represented at lights off. Alcohol,
water, and food intake was recorded 60 min later (i.e., the time
interval during which sP rats display the most pronounced ADE;
e.g., Agabio et al., 2000; Serra et al., 2003).
DATA ANALYSIS
Data on the effect of treatment with GHB on alcohol, water, and
food intake during the 60-min observation period were expressed
in g/kg, ml/kg, and g/kg, respectively, and analyzed by sepa-
rate two-way (deprivation; treatment) ANOVAs, followed by the
Newman–Keuls test for post hoc comparisons.
RESULTS
ANOVA indicated significant effects of both deprivation
[F(1, 56)= 31.99, P < 0.0001] and treatment with GHB [F(3,
56)= 6.44, P < 0.001], and a significant interaction [F(3,
56)= 3.48,P < 0.05], on alcohol intake during the first hour of the
post-deprivation phase. Alcohol intake in vehicle-treated alcohol-
deprived rats was approximately 90% higher than that recorded
in vehicle-treated alcohol-non-deprived rats (Figure 1), indica-
tive of the development of ADE. Post hoc analysis indicated that
all doses of GHB suppressed ADE, as alcohol intake in all GHB-
treated alcohol-deprived rat groups was significantly lower than
that recorded in vehicle-treated alcohol-deprived rats (Figure 1);
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FIGURE 1 | Suppressing effect of the acute administration of
γ-hydroxybutyric acid (GHB) on “alcohol deprivation effect” in
Sardinian alcohol-preferring (sP) rats. Alcohol-deprived rats were initially
allowed to consume alcohol (10% v/v, in water) and water under the
homecage two-bottle choice regimen with unlimited access for 24 h/day
and four consecutive weeks, and then deprived of alcohol for 14
consecutive days; conversely, alcohol-non-deprived rats had continuous
access to alcohol and water (with exception of the last 6 h before GHB
injection, when the alcohol bottle was removed to ensure that blood alcohol
levels were equal to zero at the time of the test). Food pellets were always
available. About 10–15 min before representation of the alcohol bottle
(which coincided with lights off), rats from both groups were injected with
GHB (0, 100, 200, and 300 mg/kg; i.p.). Alcohol intake was registered
60 min after lights off. Each bar is the mean±SEM of n=8. SP <0.0005
with respect to alcohol-non-deprived rats receiving 0 mg/kg GHB
(Newman–Keuls test); *P <0.005 and **P <0.0005 with respect to
alcohol-deprived rats receiving 0 mg/kg GHB (Newman–Keuls test).
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Table 1 | Lack of effect of the acute administration of γ-hydroxybutyric
acid (GHB) on water and food intake in Sardinian alcohol-preferring
(sP) rats exposed to the “alcohol deprivation effect” paradigm.
GHB
(mg/kg)
Water intake (ml/kg) Food intake (g/kg)
Alcohol-non
-deprived rats
Alcohol-
deprived rats
Alcohol-non-
deprived rats
Alcohol-
deprived rats
0 0.96±0.19 1.35±0.14 6.86±0.67 7.03±0.80
100 0.89±0.13 1.50±0.43 4.83±0.86 7.06±0.37
200 1.38±0.36 1.49±0.47 6.13±0.91 5.90±0.66
300 1.64±0.34 1.35±0.15 8.39±0.69 5.72±1.18
Each value is the mean±SEM of n=8.
Alcohol-deprived rats were initially allowed to consume alcohol (10% v/v, in water)
and water under the homecage two-bottle choice regimen with unlimited access
for 24 h/day and four consecutive weeks, and then deprived of alcohol for 14
consecutive days; conversely, alcohol-non-deprived rats had continuous access
to alcohol and water (with exception of the last 6 h before GHB injection, when
the alcohol bottle was removed to ensure that blood alcohol levels were equal to
zero at the time of the test). Food pellets were always available. About 10–15min
before representation of the alcohol bottle (which coincided with lights off), rats
of both groups were injected with GHB (0, 100, 200, and 300mg/kg; i.p.). Water
and food intake was registered 60min after lights off.
further, when alcohol-deprived and -non-deprived rats treated
with each GHB dose were compared, no significant difference was
recorded (Figure 1).
Finally, neither water [Fdeprivation(1, 56)= 0.78, P > 0.05;
F treatment(3, 56)= 0.57, P > 0.05] nor food [Fdeprivation(1,
56)= 0.05, P > 0.05; F treatment(3, 56)= 1.02, P > 0.05] intake
resulted to be altered by GHB treatment (Table 1).
DISCUSSION
The results of the present study indicate that acute treatment with
GHB suppressed the extra-amount of alcohol (ADE) voluntarily
consumed by alcohol-preferring sP rats after a 2-week period of
forced abstinence from alcohol. As ADE has been proposed and
validated as an animal model of relapse episodes occurring in
human alcoholics (see Spanagel, 2005; Martin-Fardon and Weiss,
2013), these data extend to relapse-like drinking the capacity of
GHB to suppress different alcohol-related behaviors, including
alcohol drinking under the two-bottle choice regimen (June et al.,
1995; Agabio et al., 1998), operant oral alcohol self-administration
(Maccioni et al., 2008), and alcohol-seeking behavior (Maccioni
et al., 2008), in alcohol-preferring rats. These data are also in
close agreement with the results of a number of clinical surveys
reporting the capacity of GHB to promote and maintain alcohol
abstinence and to prevent alcohol relapse (Gallimberti et al., 1992;
Addolorato et al., 1996, 1998; Moncini et al., 2000; Maremmani
et al., 2001; Caputo et al., 2003, 2007).
In the present study, treatment with GHB did not alter,
even minimally, food intake in either alcohol-deprived or -
non-deprived rats. These data allow to reasonably exclude that
suppression of ADE was secondary to any sedative effect of
GHB, that would have resulted in a non-specific reduction of
all consummatory behaviors. Water intake was also unaltered
by treatment with GHB; an increase in water intake (theoret-
ically compensating GHB-induced reduction in alcohol intake)
was not expected, as total fluid intake (the sum of alcohol solu-
tion and water consumed) in vehicle-treated alcohol-deprived rats
was largely higher than that required to satisfy the rats’ fluid
needs and treatment with GHB suppressed only the extra-amount
of alcohol solution consumed because of the previous alcohol
deprivation.
Data from alcohol-non-deprived rats indicate a lack of effect
of treatment with GHB on regular alcohol drinking over the 60-
min recording period. These results are consonant with those of a
previous study that temporally characterized the effect of GHB on
alcohol drinking in sP rats (Agabio et al., 1998): in the latter study,
acute administration of GHB (given at doses identical to those
used in the present study) to sP rats continuously exposed to the
two-bottle “alcohol vs. water” choice regimen dose-dependently
reduced alcohol intake only at the 15- and 30-min recording times
(i.e., taking into account the pretreatment time, 25–30 and 40–
45 min after GHB administration); at the 60-min recording time
(i.e., the same time interval of the present study), the reducing
effect of GHB on alcohol intake had already completely vanished
(Agabio et al., 1998).
The GABAB receptor constitutes the major, although not the
sole, site of action of GHB. Brain concentrations of GHB – eas-
ily reachable after administration of behaviorally active doses of
GHB (as those used in the present study) – bind directly to the
GABAB receptor, exerting agonistic properties (Mathivet et al.,
1997; Lingenhoehl et al., 1999; for review, see Bernasconi et al.,
2002). Accordingly, the results of the present study may be inter-
preted suggesting that GHB suppressed relapse-like drinking via
activation of the GABAB receptor. This interpretation is in line
with the results of recent studies demonstrating that the GABAB
receptor agonists, baclofen and CGP 44532, dose-dependently
suppressed ADE in sP rats (Colombo et al., 2003, 2006b; Carai
et al., 2005).
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